Phase 3 Crohn's Disease and Colitis Trial, Recruiting NCT07196748 Sponsor: Janssen Research & Development, LLC Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 3 Crohn's Disease and Colitis Trial, Recruiting

NCT07196748
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with ulcerative colitis (UC) for at least 12 weeks before the screening visit, confirmed by both a camera examination of the bowel and a tissue sample test
  • Your UC is considered moderately to severely active, based on a specific scoring system measured during a bowel camera examination reviewed by a central team
  • Your bowel camera examination shows a score of 2 or higher out of 3 on the inflammation rating scale, as reviewed by a central team
  • If you are a teenager taking part, you must weigh at least 40 kilograms (about 88 pounds) at the start of the study
  • If you are a woman or teenage girl who could become pregnant, you must have a negative pregnancy blood test at screening and a negative pregnancy urine test at the start of the study, and agree to further pregnancy tests during the trial
  • You have either not responded well to, or could not tolerate, standard treatments for UC — and have never tried advanced treatments (such as biologic medicines); OR you have tried advanced treatments but they did not work well enough or you could not tolerate them

Who may not be able to join:

  • You currently have serious UC complications such as a severely inflamed colon (fulminant colitis), a dangerously swollen colon (toxic megacolon), or any condition that may require colon surgery during the study
  • You currently have a stoma (a surgically created opening in the abdomen for waste removal)
  • You currently have, or have previously had, a fistula (an abnormal tunnel connecting body parts, related to your bowel condition)
  • You have had colon surgery in the 24 weeks before the study start, or any other major abdominal or significant surgery within the 12 weeks before the study start
  • You have had a large portion of your colon removed (less than 30 cm remaining), or a colon removal that would make it difficult to accurately measure how active your UC is (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Janssen Research & Development, LLC Clinical trial, Janssen Research & Development, LLC

Phone: 844-434-4210

Australian sites

Monash Health, Clayton,
Concord Repatriation General Hospital, Concord,
St Vincents Hospital Melbourne, Fitzroy,
Fiona Stanley Hospital, Murdoch,
John Hunter Hospital, New Lambton Heights,
Royal Melbourne Hospital, Parkville,
Mater Hospital Brisbane, South Brisbane,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
14 January 2028

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇨🇳 China 🇨🇿 Czechia 🇫🇷 France 🇩🇪 Germany 🇬🇷 Greece 🇭🇺 Hungary 🇮🇳 India 🇮🇱 Israel 🇮🇹 Italy 🇯🇵 Japan 🇲🇾 Malaysia 🇳🇱 Netherlands 🇵🇱 Poland 🇵🇹 Portugal 🇷🇴 Romania 🇰🇷 South Korea 🇪🇸 Spain 🇸🇪 Sweden 🇨🇭 Switzerland 🇹🇼 Taiwan Turkey (Türkiye) 🇬🇧 United Kingdom 🇺🇸 United States

7 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Double-blind (DB) Induction Study: Percentage of Adult Participants in Clinical Remission at Week I-12; DB Maintenance Study: Percentage of Adult Participants in Clinical Remission at Week M-40; Open-Label (OL) Maintenance Phase: Percentage of Adolescent Participants in Clinical Remission at Week M-40

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov